跳至主要内容
临床试验/JPRN-jRCTs051210167
JPRN-jRCTs051210167
招募中
2 期

The survival benefit of chemoradiation (Gem/nab-PTX+RT) followed by conversion surgery in patients with unresectable locally advanced pancreatic cancer: multicenter randomized phase II trial

Kobayashi Shogo0 个研究点目标入组 70 人2022年2月3日

概览

阶段
2 期
干预措施
未指定
疾病 / 适应症
Pancreatic ductal adenocarcinoma
发起方
Kobayashi Shogo
入组人数
70
状态
招募中
最后更新
2年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2022年2月3日
结束日期
待定
最后更新
2年前
研究类型
Interventional
性别
All

研究者

发起方
Kobayashi Shogo

入排标准

入选标准

  • Inclusion criteria
  • (1\) Histological or cytological evidence of pancreatic ductal carcinoma
  • (2\) Age\>\=20
  • (3\) PS:0\-1(ECOG grade)
  • (4\) Patients with unresectable locally advanced pancreatic ductal carcinoma at the first visit, which are diagnosed as being able to undergo conversion surgery after Gemcitabine\+nab\-paclitaxel therapy
  • The criteria of unresectable locally advanced cancer
  • 1\)Solid tumor contact with the SMA or CA \> 180deg
  • 2\)Solid tumor contact with the CA and aortic involvement
  • 3\)Unreconstructible SMV/PV due to tumor involvement or occlusion
  • The criteria of conversion surgery

排除标准

  • Exclusion criteria
  • (1\) Unresectable pancreatic ductal carcinoma with the following imaging criteria
  • 1\)no distant metastasis
  • 2\)no peritoneal dissemination, positive cytology
  • 3\)no para\-aortic lymph node metastasis
  • (2\) Patients with tumor involvement in organs that are difficult to treat with radiation
  • (3\) Patients with anamnesis of pulmonary fibrosis or emphysema, or patients with severe respiratory d disability
  • (for example,%VC\<\=50% or FW\|EV1\.0\<1L)
  • (4\) Patients with active infection except for viral hepatitis
  • (5\) Patients with severe general complications, for example, cardiac failure, renal failure, hepatic failure,

结局指标

主要结局

未指定

相似试验